Table 2. Survival by performance status (NSCLC and SCLC) assessed by (a) patienta and (b) oncologistb.
| Score | Median survival (months) | Cumulative survival (95% CI) at 1 year |
|---|---|---|
| (a) Patient | ||
| 0 | 12.9 | 52% (31, 73) |
| 1 | 11.3 | 40% (25, 55) |
| 2 | 6.5 | 17% (2, 33) |
| 3–4 | 2.2 | 14% (0, 32) |
| (b) Doctor | ||
| 0 | 18.9 | 67% (44, 88) |
| 1 | 8.2 | 41% (26, 57) |
| 2 | 6.5 | 17% (2, 35) |
| 3–4 | 2.1 | 17% (0, 38) |
In both cases, performance status correlated with survival (P⩽0.001). This is represented graphically in Figures 3 and 4. NSCLC=non-small-cell lung cancer; SCLC=small-cell lung cancer; CI=confidence interval.
a
Log rank test P=0.001.
b
Log rank test P<0.001.